Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14.
J Clin Oncol. 2024.
PMID: 37963304
Clinical Trial.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K.
Agarwal N, et al. Among authors: young joung j.
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
Lancet. 2023.
PMID: 37285865
Clinical Trial.
Item in Clipboard
Renal infarction caused by paradoxical embolism through a patent foramen ovale.
Jeong H, Woo Lee H, Young Joung J, Young Cho Y, Je D, Huh K, Ryoun Jang H, Huh W.
Jeong H, et al. Among authors: young joung j.
Kidney Res Clin Pract. 2012 Sep;31(3):196-9. doi: 10.1016/j.krcp.2012.06.003. Epub 2012 Jun 21.
Kidney Res Clin Pract. 2012.
PMID: 26889422
Free PMC article.
Item in Clipboard
Cite
Cite